小细胞肺癌患者血清胃泌素释放肽前体检测的临床意义

目的探讨血清肿瘤标志物胃泌素释放肽前体(ProGRP)在小细胞肺癌(SCLC)与非小细胞肺癌(NSCLC)鉴别诊断以及化疗效评估中的临床意义。方法应用酶联免疫吸附试验(ELISA)检测210例健康人、200例肺部良性疾病患者、260例NSCLC患者和182例SCLC患者化疗前后血清中ProGRP水平。结果 SCLC患者血清中ProGRP水平明显高于NSCLC组、健康对照组和肺部良性疾病组(P0.01)。ProGRP对SCLC检测的敏感性为56.3%,特异性为92.6%;SCLC患者经过2个周期化疗后,ProGRP水平明显低于化疗前(P0.01)。结论肿瘤标志物ProGRP对于SCLC的辅助诊断、鉴别诊断以及化疗效评估有非常重要的临床指导意义。

Clinical significance of serum ProGRP detection in patients with small cell lung cancer

Objective To investigate the clinical significance of precursor of gastrin‐releasing peptide(ProGRP) for the differen‐tial diagnosis between small cell lung cancer (SCLC) and non‐small cell lung cancer(NSCLC) and efficacy assessment .Methods The levels of ProGRP were detected by ELISA in 210 healthy adults ,200 patients with lung benign disease ,260 patients with NSCLC and 182 patients with SCLC before treatment and after chemotherapy .Results The level of ProGRP in the SCLC group was significantly higher than that in the NSCLC group ,healthy control group and lung benign disease group(P<0 .01) .The sensi‐tivity of ProGRP for detecting SCLC was 56 .3% and the specificity was 92 .6% .When combination detection of ProGRP and NSE was used ,the sensitivity increased to 82 .6% ;the level of ProGRP in the patients with SCLC after 2‐cycle chemotherapy was signifi‐cantly lower than before treatment (P<0 .01) .Conclusion The tumor marker ProGRP has very important guidance significance to assisted diagnosis ,differential diagnosis and efficacy assessment of chemotherapy in the patients with SCLC .